# Mechanistic Insights into Lactobacillus harbinensis and Other Probiotics Regulating Lipid Metabolism in T2DM Mice via the PPARγ-LXRα-NPC1L1 Signaling Pathway Based on Multi-Omics Analysis

**Authors:** Baheban Yeerjiang, Tabusi Manaer, Xuelian Liu, Reziya Bieerdimulati, Xinhua Nabi

PMC · DOI: 10.3390/metabo16030157 · 2026-02-27

## TL;DR

This study shows how a probiotic mix from fermented camel milk improves diabetes and lipid metabolism in mice by changing gut bacteria and a key signaling pathway.

## Contribution

The study reveals a novel multi-omics mechanism linking probiotics to lipid metabolism via the PPARγ-LXRα-NPC1L1 pathway in T2DM.

## Key findings

- CPCM improved glucose and lipid metabolism while enriching beneficial gut bacteria like Lactobacillus and Akkermansia.
- Proteomic analysis showed CPCM restored key proteins in fatty acid oxidation and PPAR signaling.
- EPS from CPCM upregulated PPARγ and LXRα while inhibiting NPC1L1 in Caco-2 cells.

## Abstract

Background/Objectives: Intestinal dysbiosis is a pivotal trigger of type 2 diabetes mellitus (T2DM). Our previous studies confirmed that composite probiotics derived from fermented camel milk (CPCM), containing Lactobacillus harbinensis and 13 other strains, can ameliorate glucose and lipid metabolism in T2DM mice by reshaping bile acid profiles, and its effect may be associated with the PPARγ-LXRα-NPC1L1 signaling pathway. Methods: Metagenomic analysis characterized alterations in intestinal microbiota structure and functional genes post-CPCM intervention, proteomic analysis detected changes in protein expression profiles related to glucose and lipid metabolism in mice, and Caco-2 cells were used for in vitro validation to clarify the regulatory effect of exopolysaccharides (EPS) (the active component of CPCM) on the PPARγ-LXRα-NPC1L1 signaling pathway. Results: The results showed that CPCM significantly improved glucose and lipid metabolism and remodeled the intestinal flora structure in mice, markedly enriching beneficial bacteria such as Lactobacillus and Akkermansia and enhancing the expression of functional genes related to the peroxisome proliferator-activated receptor (PPAR) signaling pathway and short-chain fatty acid synthesis in the microbiota. Proteomic analysis revealed that CPCM reversed the expression of key proteins involved in fatty acid oxidation and transport, thereby restoring the function of the PPAR signaling pathway. In vitro experiments validated that extracellular polysaccharides, the active component of CPCM, significantly upregulated the expression of PPARγ and liver X receptor α (LXRα) and inhibited the expression of Niemann–Pick C1-Like 1 (NPC1L1), a cholesterol absorption transporter, in Caco-2 cells. Conclusions: In conclusion, CPCM ameliorates glucose and lipid metabolic disorders in T2DM through multiple mechanisms: reshaping the intestinal probiotic community, enhancing its beneficial metabolic functions, restoring the activity of the PPARγ-LXRα signaling pathway, and subsequently downregulating NPC1L1.

## Linked entities

- **Genes:** PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468], NR1H3 (nuclear receptor subfamily 1 group H member 3) [NCBI Gene 10062], NPC1L1 (NPC1 like intracellular cholesterol transporter 1) [NCBI Gene 29881]
- **Diseases:** type 2 diabetes mellitus (MONDO:0005148), T2DM (MONDO:0005148)
- **Species:** Akkermansia (taxon 239934), Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Fabp4 (fatty acid binding protein 4, adipocyte) [NCBI Gene 11770] {aka 422/aP2, AFABP, ALBP, ALBP/Ap2, Ap2, Lbpl}, Cfd (complement factor D) [NCBI Gene 11537] {aka Adn, DF}, Atg13 (autophagy related 13) [NCBI Gene 51897] {aka 1110053A20Rik, D2Ertd391e, Harbi1}, NPC1L1 [NCBI Gene 105080690], ACOX1 (acyl-CoA oxidase 1) [NCBI Gene 51] {aka ACOX, AOX, MITCH, PALMCOX, SCOX}, Npc1l1 (NPC1 like intracellular cholesterol transporter 1) [NCBI Gene 237636] {aka 9130221N23Rik, Gm243}, NR1H3 (nuclear receptor subfamily 1 group H member 3) [NCBI Gene 10062] {aka LXR-a, LXRA, RLD-1}, Fabp7 (fatty acid binding protein 7, brain) [NCBI Gene 12140] {aka B-FABP, BFABP, Blbp, MRG}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Acox2 (acyl-Coenzyme A oxidase 2, branched chain) [NCBI Gene 93732] {aka THCCox}, Acox1 (acyl-Coenzyme A oxidase 1, palmitoyl) [NCBI Gene 11430] {aka AOX, Acox, D130055E20Rik, Paox}, GPBAR1 (G protein-coupled bile acid receptor 1) [NCBI Gene 151306] {aka BG37, GPCR19, GPR131, M-BAR, TGR5}, Fabp3 (fatty acid binding protein 3, muscle and heart) [NCBI Gene 14077] {aka Fabph-1, Fabph-4, Fabph1, Fabph4, H-FABP, Mdgi}, Got2 (glutamatic-oxaloacetic transaminase 2, mitochondrial) [NCBI Gene 14719] {aka FABP-pm, Got-2, Kyat4, mAspAT}, PYY [NCBI Gene 105072563], Nr1h3 (nuclear receptor subfamily 1, group H, member 3) [NCBI Gene 22259] {aka LXR, RLD1, Unr1}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}, Fabp1 (fatty acid binding protein 1, liver) [NCBI Gene 14080] {aka Fabpl, L-FABP}, Fabp2 (fatty acid binding protein 2, intestinal) [NCBI Gene 14079] {aka Fabpi, I-FABP}, Ppara (peroxisome proliferator activated receptor alpha) [NCBI Gene 19013] {aka 4933429D07Rik, Nr1c1, PPAR-alpha, PPARalpha, Ppar}, Rxra (retinoid X receptor alpha) [NCBI Gene 20181] {aka 9530071D11Rik, Nr2b1, RXRalpha1}, MyD88 [NCBI Gene 105061728], NPC1L1 (NPC1 like intracellular cholesterol transporter 1) [NCBI Gene 29881] {aka LDLCQ7, NPC11L1, SLC65A2}, Pparg (peroxisome proliferator activated receptor gamma) [NCBI Gene 19016] {aka Nr1c3, PPAR-gamma, PPAR-gamma2, PPARgamma, PPARgamma2}, LIMA1 (LIM domain and actin binding 1) [NCBI Gene 51474] {aka EPLIN, LDLCQ8, SREBP3}
- **Diseases:** DM (MESH:D003920), cytotoxicity (MESH:D064420), impaired glucose tolerance (MESH:D018149), Intestinal dysbiosis (MESH:D064806), abnormal hepatic lipid metabolism (MESH:D052439), obesity (MESH:D009765), T2DM (MESH:D003924), injury to (MESH:D014947), insulin resistance (MESH:D007333), inflammation (MESH:D007249), hypercholesterolemic (MESH:D006938), metabolic disease (MESH:D008659)
- **Chemicals:** propionate (MESH:D011422), Trichloroacetic acid (MESH:D014238), TEAB (MESH:C041737), TG (MESH:D014280), Trizol (MESH:C411644), Lipid (MESH:D008055), TCEP (MESH:C080938), polysaccharide (MESH:D011134), T-alpha-MCA (MESH:C037351), formazan (MESH:D005562), sodium cholate (MESH:D020358), sodium taurocholate (MESH:D013656), Fatty acid (MESH:D005227), ethanol (MESH:D000431), CDCA (MESH:D002635), TFA (MESH:D014269), cortisol (MESH:D006854), Cholesterol (MESH:D002784), agarose (MESH:D012685), CPCM (-), water (MESH:D014867), MTT (MESH:C070243), LCA (MESH:D008095), SCFA (MESH:D005232), saline (MESH:D012965), Glucose (MESH:D005947), butyrate (MESH:D002087), formic acid (MESH:C030544), acetate (MESH:D000085), aldosterone (MESH:D000450), LPS (MESH:D008070), diazepam (MESH:D003975), IAM (MESH:D007460), metformin (MESH:D008687), endocannabinoid (MESH:D063388), DMSO (MESH:D004121), amino acid (MESH:D000596), bile acid (MESH:D001647), C-Peptide (MESH:D002096), blood glucose (MESH:D001786), acetonitrile (MESH:C032159)
- **Species:** Desulfovibrio (genus) [taxon 872], Roseburia (genus) [taxon 841], Lactobacillus acidophilus (species) [taxon 1579], Agathobacter rectalis (species) [taxon 39491], Homo sapiens (human, species) [taxon 9606], Lactobacillus sp. (species) [taxon 1591], Schleiferilactobacillus harbinensis (species) [taxon 304207], Duncaniella (genus) [taxon 2518495], Leptospira sp. AB (species) [taxon 103236], Ruminococcus (genus) [taxon 1263], Fusobacterium (genus) [taxon 848], Mus musculus (house mouse, species) [taxon 10090], Akkermansia (genus) [taxon 239934], Lactobacillus helveticus (species) [taxon 1587], Bacteroides (genus) [taxon 816], Escherichia coli (E. coli, species) [taxon 562], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Kluyveromyces marxianus (species) [taxon 4911], Pichia kudriavzevii (species) [taxon 4909], Bifidobacterium (genus) [taxon 1678], Clostridium (genus) [taxon 1485]
- **Mutations:** K306fs
- **Cell lines:** Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13027407/full.md

---
Source: https://tomesphere.com/paper/PMC13027407